FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
556 letters match. Newest first.
-
DrugsWoodbine Products Company Inc.
Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.
High risk -
DrugsThomas Brunner Hygiene GmbH
Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.
High risk -
DrugsDabur India Limited
FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.
High risk -
DrugsABS Corporation
ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.
High risk -
DrugsAHC Products, Inc.
AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.
High risk -
DrugsIsland Kinetics, Inc. d.b.a. CoValence Laboratories
Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.
High risk -
DrugsAlmon Healthcare Private Limited
Almon Healthcare, an Indian active pharmaceutical ingredient (API) maker, knowingly used mislabeled, untested raw material and shipped affected drugs to the U.S.
High risk -
DrugsBioMylz Pvt. Ltd.
FDA found destroyed records, inadequate process and cleaning validation, missing microbial testing, and incomplete drug listings at BioMylz, an Indian OTC drug manufacturer.
High risk -
DrugsShimoga Chemicals
FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.
High risk -
DrugsFareva Amboise
FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.
High risk -
DrugsSpa De Soleil, Inc.
FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.
High risk -
DrugsInternational Medication Systems Limited
FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.
High risk -
DrugsExcelvision - Fareva
FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.
High risk -
DrugsWizcure Pharmaa Private Limited
FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.
High risk -
DrugsYangzhou Hongshengding Chemical Co., Ltd.
Yangzhou Hongshengding Chemical refused FDA records requests for its over-the-counter drugs, leading to an import alert.
High risk -
DrugsHuons Co., Ltd.
FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.
High risk -
DrugsJubilant HollisterStier General Partnership
FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.
High risk -
DrugsSante Manufacturing Inc.
Sante Manufacturing’s OTC drugs have significant CGMP violations, including missing identity testing for a high-risk component and inadequate process validation and quality oversight.
High risk -
DrugsPharmathen International S.A.
FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.
High risk -
DrugsHubei Gedian Humanwell Pharmaceutical Co., Ltd.
FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.
High risk -
DrugsGopaldas Visram & Co., Ltd.
FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.
High risk -
DrugsLaboratorios Dr. Collado S.A.
FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.
High risk -
DrugsRevlon Group Holdings, LLC
FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.
High risk -
DrugsUmendra Life Sciences Private Limited
Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.
High risk -
DrugsErkul Kozmetik Sanayi ve Ticaret A.S.
Erkul Kozmetik failed to test talc in OTC drugs for identity and asbestos, violating manufacturing rules.
High risk -
DrugsPLZ Corp
FDA warned PLZ Corp over an OTC talc drug made in Mississauga without asbestos testing and with deficient component controls.
High risk -
DrugsAsanuma Corporation - Sagamihara Factory
FDA warned Japan's Asanuma Sagamihara factory, an OTC drug maker, that its talc was never tested for asbestos.
High risk -
DrugsShantou Qiwei Industry Co., LTD
FDA warns Shantou Qiwei, a Chinese OTC drug maker, that it never tested talc for asbestos, making its products adulterated.
High risk -
DrugsZydus Lifesciences Limited
FDA warns Zydus Lifesciences over untested asbestos in talc used in its prescription drugs and altered lab data at its Himachal Pradesh plant.
High risk -
DrugsMacau-Union Pharmaceutical Limited
Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.
High risk -
DrugsMedline Inc
FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.
High risk -
DrugsLaboratorios Jaloma S.A. de C.V.
FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.
High risk -
DrugsAeroflex Industria de Aerosol Ltda.
Brazil OTC drug maker Aeroflex ignored FDA records requests, prompting possible approval holds and US shipment refusals.
High risk -
DrugsAlchymars ICM SM Private Limited
FDA found Alchymars API manufacturing had poor equipment and facility maintenance, making its APIs adulterated and prompting an import alert.
High risk -
DrugsSato Pharmaceutical Co., Ltd.
FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.
High risk -
DrugsGC America, Inc.
FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.
High risk -
DrugsHarbin Jixianglong Biotech Co., Ltd.
FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.
High risk -
DrugsHangzhou Yiqi Biotechnology Co., Ltd
FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.
High risk -
DrugsJW Nutritional LLC
FDA warns JW Nutritional over serious CGMP failures in OTC drug manufacturing, including untested components and inadequate microbial limits.
High risk -
DrugsIDO Pharm Co., Ltd.
IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.
High risk -
DrugsNaveh Pharma LTD/Bigdam Inc.
FDA says Naveh Pharma and Bigdam sell unapproved saline drug products in the U.S. and have no quality unit.
High risk -
DrugsCareFusion 213, LLC
FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.
High risk -
DrugsActive Cosmetics Manufacturing Inc.
FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.
High risk -
DrugsRespilon Production S.R.O.
FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.
Medium -
DrugsAva Inc.
FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.
High risk -
DrugsFoshan Miwei Cosmetics Co., Ltd.
FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.
High risk -
DrugsLexia LLC
FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.
High risk -
DrugsIntas Pharmaceuticals Limited
FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.
High risk -
DrugsPar Health USA, LLC & Endo USA, Inc.
FDA cited Par Health USA/Endo USA’s Rochester plant for sterile injectable contamination-control, media fill, and visual inspection failures after an October 2025 inspection.
High risk -
DrugsNew Life Pharma LLC
New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.
High risk